Strategic question
Which oncology ventures in emerging markets can offer advice, patient cohorts or clinical trial capability at scale?
How Galen Growth helped
From market signal to decision-ready evidence
Combining HealthTech Alpha with structured ecosystem mapping, we evaluated 113 oncology-focused ventures across eight markets and built a highly prioritised target list aligned to clinical trial and cohort criteria.
Outcomes
Reframed emerging markets as credible clinical execution partners rather than peripheral geographies, and surfaced the specific ventures with partnership potential.
Decision enabled: Enabled the clinical and BD teams to engage a short, highly qualified list of oncology ventures for further evaluation.
Key results
Our approach
A repeatable path to a defensible decision
Define
Clarify the strategic question, decision owner, market boundaries, and success criteria.
Map
Identify the relevant ventures, markets, competitors, partnerships, and evidence signals.
Assess
Evaluate maturity, traction, clinical relevance, commercial fit, and operational readiness.
Decide
Translate the evidence into a shortlist, benchmark, market view, or portfolio recommendation.
Related work
More digital health case studies
Tracking Competitor Moves to Support Global Franchise Strategy
How should we track competitor activity across obesity, diabetes and cardiovascular disease to support global strategic decisions?
Prioritising Markets and Partners to Accelerate a Women’s Health Roadmap
Which priority markets and venture partners should anchor our future women’s health innovation roadmap, starting with telemedicine?
Benchmarking Global Competitor Partnerships to Prioritise Digital Health Strategy
Where are competitors investing and partnering in Digital Health, and what should that mean for our own portfolio strategy?